Neuroprotective effect of a nasal formulation of erythropoietin with low sialic acid content;Efecto neuroprotector de una formulación nasal de eritropoyetina con bajo contenido de ácido siálico

Revista Cubana de Farmacia

Volumn 43, Issue 1, 2009, Pages

  Nuñez Figueredo, Yanier ^a   Bueno Pavón, Viviana ^a   Carrillo Domínguez, Carmen ^a   Jiménez Alemán, Narda ^a   Valdés Martínez, Odalys ^a   Montero Alejo, Vivian ^a   Muñoz Cernuda, Adriana ^a   Alonso Jiménez, Esther ^a  

^a CENTRO DE INVESTIGACIÓN Y DESARROLLO DE MEDICAMENTOS CIDEM   (Cuba)

Author keywords

Cerebral ischemia; Erythropoietin; Intranasal administration; Neuroprotection

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN PROTECTION; CONTROLLED STUDY; HIPPOCAMPUS; HISTOPATHOLOGY; MALE; NEUROPROTECTION; NONHUMAN; RAT;

EID: 67149104313     PISSN: 00347515     EISSN: 15612988     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Talegaonkar S, Mishra PR. Intranasal delivery: An approach to bypass the blood-brain barrier. Indian J Pharmacol. 2004; 36:140-147 (Pubitemid 38787065)
2. Sayeed I, Guo Q, Hoffman SW, Stein DG. Allopregnanolone, a Progesterone Metabolite, Is more effective than progesterone in reducing cortical infarct volume after transient middle cerebral artery occlusion. Ann Emerg Med. 2006; 47:381-389
3. Siren AL, Ehrenreich H. Erythropoietin -a novel concept for neuroprotection. Eur Arch Psychiatry Clin Neurosci. 2001; 251(4):179. (Pubitemid 32963495)
4. Digicaylioglu M, Garden G, Timberlake S, Fletcher L, Lipton SA. Acute neuroprotective synergy of erythropoietin and insulin-like growth factor I. Proc Natl Acad Sci USA. 2004; 101(26):9855-9860 (Pubitemid 38869326)
5. Coert BA, Anderson RE, Meyer FB. Reproducibility of cerebral cortical infarction in the Wistar rat after middle cerebral artery occlusion. J Stroke Cerebrovasc Dis. 1999; 8:380-387
6. Lipton P. Ischemic cell death in brain neurons. Physiological Rev. 1999; 79 (4):1432-1568 (Pubitemid 29473320)
7. Tamura A, Graham DI, Teasdale GM. Focal cerebral ischaemia in the rat: 1. Description of technique and early neuropathological consequences following middle cerebral artery occlusion. J Cereb Blood Flow Metabol. 1981; 1:53-60.
8. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989; 20:84-91. (Pubitemid 19040218)
9. Minematsu K, Li L, Sotak CH, Davis MA, Fisher M. Reversible focal ischemic injury demonstrated by diffusion-weighted magnetic resonance imaging in rats. Stroke. 1992; 23:1304-1310
10. González FA, Eduardo Candelario EJ, García CM, León SO. Effects of pyruvate administration on infarct volume and neurological deficits following permanent focal cerebral ischemia in rats. Brain Res. 2003; 990:1-7. (Pubitemid 37244055)
11. Sigarroa A, Biometría y diseño experimental. La Habana: Ed. Pueblo y Educación; 1985. p. 430.
12. Farooqui AA, Haun SE, Horrocks LA. Ischemia and hypoxia. In: GJ Siegel. Basic Neurochemistry: Molecular, cellular and medical aspects. 5th ed. New York: Raven Press; 1994. p. 867-883
13. Dirnagl U, Iadecola C, Moskowitz M.A. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999; 22:391-397 (Pubitemid 29453643)
14. Lo EH, Dalkara T, Moskowitz MA. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci. 2003; 4:399-415.
15. García S JD. Protección neuronal endógena: un enfoque alternativo. Rev Neurol. 2004;38(2):150-155 (Pubitemid 38252140)
16. Shingo T, Soracan ST, Shimazaki T, Weis S. Erythropoietin regulates the in vitro and production of neuronal progenitors be mammalian forebrain neural stem cells, J Neurosci. 2001; 21:9733-9743 (Pubitemid 34184059)
17. Brines ML, Ghezzi P, Keenan S. Erythropoietin cross the blood brain barrier to protect against experimental brain injury. Proc Natl Acad Sci. 2000; 97:10526-10531 (Pubitemid 30707300)
18. Sakanaka M, Wen T-C, Matsuda S, Seiji Masuda S, Morishita E, Nagao M, Sasaki R. In vivo evidence that erythropoietin protects neurons from ischemic damage. PNAS. 1998;95:4635-4640
19. Eid T, Brines M. Recombinant human erythropoietin for neuroprotection: what is the evidence? Clin Breast Cancer. 2002; Suppl 3:109-115
20. Marti HH, Bernaudin M, Petit E, Bauer C. Neuroprotection and angiogenesis: Dual role of erythropoietin in brain ischemia. News Physiol Sci. 2000;15:225-229
21. Bernaudin M, Marti HH, Roussel S, Divoux D, Nouvelot A, Mackenzie ET, Petit E. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab. 1999; 19:643-651 (Pubitemid 30161216)
22. Siren AL, Ehrenreich H. Erythropoietin: a novel concept for neuroprotection. Eur Arch Psychiatry Clin Neurosci. 2001; 251:179-184
23. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature. 2001;412:641-647 (Pubitemid 32772276)
24. Maiese K, Li F, Chong ZZ. New Avenues of Exploration for Erythropoietin JAMA. 2005; 293:90-95
25. Toyoda T, Arakawa T, Aoki K, Yamaguchi H. Stabilization of human recombinant erythropoietin through interactions with the highly branched N-glycans. J Biochem 2000; 128:731-7.
26. Jelkmann W. The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP. Eur J Haematol. 2002; 69:265-74. (Pubitemid 36005815)
27. Dordal MS, Wang FF, Goldwasser E. The role of carbohydrate in erythropoietin action. Endocrinology. 1985; 116:2293-2299 (Pubitemid 15098058)
28. Weikert S, Papac D, Briggs J. Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins. Nature Biotechnol. 1999; 17:1116-1121 (Pubitemid 29533554)
29. Goldwasser E, Kung CK, Eliason J. On the mechanism of erythropoietin-induced differentiation. The role of sialic acid in erythropoietin action. J Biol Chem. 1974; 249:4202-4206
30. Wiessner C, Allegrini PR, Ekatodramis D, Jewell UR, Stallmach T, Gassmann M. Increased cerebral infarct volumes in polyglobulic mice overexpressing erythropoietin. J Cereb Blood Flow Metab. 2001; 21:857-864 (Pubitemid 32613540)
31. Gassmann M, Heinicke K, Soliz J, Ogunshola OO. Non-erythroid functions of erythropoietin. In: Roach RC. Hypoxia: Through the Lifecycle. Chapter 21. New York: Kluwer Academic/Plenum Publishers; 2003.
32. Ajmani RS, Metter EJ, Jaykumar R. Hemodynamic changes during aging associated with cerebral blood flow and impaired cognitive function. Neurobiol Aging. 2000; 21:257-269 (Pubitemid 30387084)
33. Banks AW. Are the extracelluar pathways a conduit for the delivery of therapeutics to the brain? Current Pharmaceutical Design. 2004; 10:1365-1370
34. Frey HW, Liu J, Chen X, Thoner RG, Fawcett JR. Delivery of 125 I-NGF to the brain via the olfactory route. Drug Delivery. 1997; 4:87-92. (Pubitemid 27276124)
35. Sosa TI. Estudio del efecto neuroprotector de la eritropoyetina humana recombinante con bajo contenido de ácido siálico aplicada por vía intranasal en biomodelos experimentales de isquemia cerebral. Tesis Doctoral, La Habanaa. CENPALAB; 2007.
36. Yu YP, Xu QQ, Zhang Q, Zhang WP, Zhang LH, Wei EQ. Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia. Neurosci Lett. 2005;387(1):5-10. (Pubitemid 41138199)
37. Sosa TI, García R JC, García S JD, Santana J, Subirós MN, González TC, et al. Intranasal administration of recombinant human erythropoietin exerts neuroprotective effects on post-ischemic brain injury in mongolian gerbils. Pharmacology Online. 2006(1):100-112
38. Joshi CN, Jain SK, Murthy PS. An optimized triphenyltetrazolium chloride method for identification of cerebral infarcts. Brain Res Brain Res Protoc. 2004;13(1):11-17 (Pubitemid 38519594)